Skip to content

Optimizing Chronic Pain Treatment With Enhanced Neuroplastic Responsiveness

Optimizing Chronic Pain Treatment With Enhanced Neuroplastic Responsiveness

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02681081
Acronym
OPTIMIZE
Enrollment
26
Registered
2016-02-12
Start date
2016-02-29
Completion date
2019-07-12
Last updated
2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis, Pain

Keywords

Neuroplasticity

Brief summary

The purpose of the study is to identify non-invasive strategies that will optimize the neurobiological environment and improve learning and memory in the treatment of chronic pain. The overall aims of the current proposal are to determine if food restriction and/or glucose administration in conjunction with a relaxation/guided imagery exercise will result in neurophysiological changes and functional improvements compared to the relaxation/guided imagery exercise alone.

Detailed description

Up to sixty adults with chronic knee pain with or/at risk of knee osteoarthritis will be randomized to one of three groups: food restriction (20 participants), glucose administration (20 participants), or control (20 participants). Participants will attend four sessions over a two to three week period.

Interventions

OTHERGlucose Administration

For sessions 2 through 4, participants will fast for two hours prior to each session and consume 25-30 g of glucose at the start of each session.

OTHERIntermittent Fasting

For sessions 2 through 4, participants will fast for 16 hours prior to the session (no food or beverages other than non-caloric beverages or coffee after 6 or 7 pm the evening prior).

OTHERControl

Normal food intake

Sponsors

American Pain Society
CollaboratorOTHER
University of Florida
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

* Adults with chronic knee pain with or/at risk of knee osteoarthritis

Exclusion criteria

* Concurrent medical condition that could confound outcome measures or limit the ability to participate completely in the protocol including: neurological conditions (Parkinson's disease, multiple sclerosis, and/or seizures) * History of a head injury or stroke * Diabetes or taking medications to control blood sugar * Mental health issues resulting in hospitalization or outpatient treatment in the past year, and/or psychotropic medication use * Current issue or history of treatment for alcohol or other substance abuse * Cognitive function \< or = 22 on the Mini-Mental Status Exam * Pregnancy * A baseline fasting blood sugar (plasma glucose \> 7mmol/L) or persisting blood pressure \>150/95. * Heart condition such as a prior heart attack, heart surgery (including a stent), frequent chest pain or heart failure * Inability to complete the EEG portion of the study

Design outcomes

Primary

MeasureTime frameDescription
Change in Neurophysiological measuresbaseline and 3 weeksElectroencephalogram (EEG) amplitude measures.

Secondary

MeasureTime frameDescription
Change in Clinical Pain measure - Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)baseline and 3 weeksMeasure of lower extremity pain and function in persons with knee OA.
Change in Experimental Pain measure - Temporal summation of punctate mechanical stimulibaseline and 3 weeksQuantitative sensory testing measure.
Change in Level of Distress measure - Perceived Stress Scalebaseline and 3 weeksMeasure of perceived stress.
Change in Affect Measure - Positive and Negative Affect Schedule (PANAS)baseline and 3 weeksMeasure of positive and negative affect.

Other

MeasureTime frameDescription
Change in Recall and Recognition measures - Hopkins Verbal Learning Test (HVLT)baseline and 3 weeksMeasure of verbal learning/memory

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026